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ABSTRACT
Purpose: To determine the feasibility of radiation dose escalation> 70 Gy to Gross Tumour Volume (GTV) using
3-Dimensional Conformal Radiotherapy (3-DCRT).
Methods and Materials: From December 1997 to November 1998, 22 patients with non-small cell lung cancer
(NSCLC) were included. Tumour stage was I in 3 cases, II in 6 cases, III in 10 cases, and there were 3
locoregional recurrences after surgery. A 3-D treatment planning system with BEV was used for all patients.
patients underwent limited elective nodal irradiation of 56 Gy. The GTV with 1 em margin received a dose of at
least 70 Gy. Acute and late toxicity were estimated according to the RTOG/EORTC score.
Results: The mean follow-up was 217 (80-360) days. Seventeen patients received 74 Gy, two had 72 Gy, and
one had 70 Gy. In one patient with the largest irradiation volume a toxic death due to radiation pneumonitis
occured. Except this fatality acute toxicity was acceptable. Seventeen patients were evaluable for response.
There were 3 (18%) complete responses, all in patients staged I and fl, seven (41%) partial responses, 5 (29%)
non-responses and two (12%) local progressions. Two local progressions and two distant failures occured in
stage III patients.
Conclusions: Dose escalation >70 Gy using 3-DCRT in management of NSCLC is .feasible with acceptable
acute toxicity.
INTRODUCTION
Radiotherapy is one of the major modalities
used in the treatment of non-small cell lung
cancer (NSCLC ), however a local control rate
following conventional radiation therapy remains
poor. In view of the poor efficacy of radiotherapy
in management of NSCLC there is a clear need
for improvement in the therapeutic ratio of this
method. Radiation dose escalation is one of the
means used for enhancement of the local
control disease, but this technique may cause a
prohibitive toxicity. Three-dimensional conformal
radiotherapy (3-DCRT) enhances the thera-
peutic ratio by increasing the probability of cure
due to increased target dose and decreased
toxicity through minimizing the radiation dose to
healthy tissues. Recent technological advances
in the areas of treatment planning and delivery
systems have made possible to achieve both
effects in several clinical studies (Emami et aI.,
1991; Armstrong et aI., 1997; Robertson et al.,
1997; Derycke et aI., 1997). In this study the
possibility of implementation of a 3-DCRT in
view of dose escalation in management of
NSCLC has been investigated.The purpose was
to determine the feasibility of radiation dose
escalation >70 Gy to gross tumour volume
(GTV) using a 3-DCRT. In addition, the survival
rate and the pattern of locoregional failure have
also been examined.
MATERIAL AND METHODS
Twenty two patients, 6 females and 16 males,
aged 50-75, numbered 1 to 22, were included in
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the study between December 1997 and
November 1998. The histology type was found
to be squamous cell carcinomas in 13 patients,
bronchio-alveolar carcinoma in one patient,
large cell carcinomas in two patients and 6 non-
small cell carcinomas without further
specification. Tumour stage according to the
TNM UICC classification was I in 3 cases, stage
II in 6 cases, lilA in 7 cases, IIIB in 3 cases.
Three locoregional recurrences were observed
after surgery (rT2N1 MO, rTON2MO, rT3N2MO).
Table 1 shows the number of patients, age, sex,
histology, stage, performance status and weight
loss. Ten patients were found to be inoperable
because of medical problems (cardio-pulmonary
diseases), and 12 patients were unresectable.
Patients with stage III of the disease were not
eligible for chemo-radiotherapy protocols, which
is a routine treatment policy in these cases in
our department, because of significant medical
problems involved. Pre-treatment evaluation
included a physical examination, complete blood
count, chest X-ray, bronchoscopy, CT scan of
the chest and upper abdomen, CT or MRI of the
brain and bone scan. The clinical trial was
approved by the Ethical Committee of the
Institute, with prior informed consent of all
patients haVing been obtained.
No of patient, Histology Stage KPS Weight loss
age,sex
P1, 72, M NSCLC IliA 80 NO
P2, 75, M SCC IIIB 80 <10%
P3,50, F NSCLC lilA 80 <10%
P4, 70, M SCC rlliA 90 NO
P5, 74, M NSCLC II 90 <10%
P6, 52, M SCC lilA 70 >10%
P7, 63, M SCC lilA 80 <10%
P8, 60, M -SCC IIIB 90 NO
P9,69,F SCC I 80 <10%
P10, 69, M BAC rlliA 90 NO
P11, 67, M NSCLC I 80 NO
P12,67,F NSCLC II 80 <10%
P13, 61, M SCC II 90 <10%
P14,53,F SCC II 80 <10%
P15,67,F LCC lilA 70 >10%
P16, 68, M SCC IliA 80 >10%
P17, 64, M LCC IIIB 80 NO
P18, 73, M SCC I 70 NO
P19, 66, M SCC II 80 <10%
P20, 63, M SCC lilA 70 >10%
P21, 69, M SCC rll 70 >10%
P22,66,F NSCLC II 90 NO
Abbreviations: M=male, F=female, NSCLC= non-small cell lung cancer without specification,
SCC= squamous cell carcinoma, BAC=bronchio-alveolar carcinoma, LCC= large cell
carcinoma
Table 1. Patient's characteristics
A 3-D treatment planning system (TMS-Helax)
was used for all patients after computed
tomography including the entire lung volume. CT
scans were done at 1 cm intervals through
regions with no visible involvement and at 5 mm
slices through the GTV. Three different clinical
target volumes were contoured, of which the
PTV1 was the largest one and included PTV2,
which in turn included PTV3, as described
30
below. PTV1 included GTV and the region of
subclinical disease (uninvolved ipsilateral hilar,
mediastinal, subcarinal nodes, - generally
ipsilateral groups 2,3,4,5,6,7,10 and
heterolateral groups 4 for the left side and
heterolateral group 4, 5 for the right side
according to the classification of AJCC and
ATS) with 1-1.5 cm margins within lungs and 2
cm margins within mediastinal tissues. PTV2
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included GTV, uninvolved ipsilateral hilar (group
10), subcarinal (group 7), lower paratracheal
(group 4) and aortico-pulmonary window nodes
(group 5) with 1 em margins within lungs and 2
cm within mediastinum. PTV3 consisted of GTV
with 1 cm margins. GTV was defined as tumour
visible at CT and bronchoscopy plus the lymph
nodes with a diameter on CT scans larger than
2 em. PTV1 received a dose of 40-44 Gy, and
the dose to PTV2 reached 56 Gy. PTV3 was
irradiated to the highest possible dose of not
less than 70 Gy. The dose was prescribed to the
isocentre, located at the geometric centre of the
PTV. Specific dose constraints for critical
structures were observed. The dose to the
spinal cord did not exceed 50 Gy. At least 50%
of the lung volume received less than 20 Gy and
the mean dose for both lungs outside the PTV3
was inferior to 20 Gy. The length of the
oesophagus receiving over 60 Gy did not
exceed 10 cm. The entire heart volume received
less than 40 Gy. The critical structures tolerance
was inferred from the DVH analysis. The
maximum rate of dose inhomogeneity for PTV3
was set at 10%. Beam incidences were
established using the BEV. Optimization tools
were used for each stage of the treatment
(irradiation of each PTV) in order to meet the
criteria for tolerance and deliver the maximum
achievable dose to PTV3. Custom blocks were
used to minimise the dose delivered to healthy
adjacent tissues. Figure 1 shows example of
added dose plan in coronal section. Figures 2,
3, 4 show dose distribution in transversal section
for PTV1, PTV2 and PTV3 respectively. The
dose per fraction was 2 Gy (corrected for tissue
inhomogeneity), delivered once a day, five times
per week. In all patients, 4 MV photons were
used. Port films checks were made every week.
All patients were evaluated once per week
during treatment. During the follow-up, patients
were seen initially 6 weeks after treatment, and
then every 3 months. Evaluation included
physical examination with assesement of the
Karnofsky Performance Status (KPS) and
measurements of weight, complete blood
counts, liver functions tests and chest X-rays.
CT of the thorax was performed within three
months after the end of radiotherapy and then
every 6 months. Acute and late toxicity was
estimated according to the criteria of the
RTOG/EORTC scoring system (Cox et aI., 1995).
Fig. 1. Added dose plan for P1V1, P1V2, P1V3; example of dose distribution in coronal section
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Fig. 4. Dose distribution for PTV3 in transversal section.
RESULTS
The mean follow-up was 217 days ranging
from 80 to 360 days. Two patients were
excluded from analysis, because they did not
receive the prescribed dose. One of them did
not complete the treatment because of
dissemination which occured during radiation
therapy and in the other because of a
significant error in treatment delivery. The
details of the radiation therapy plan and
technique, toxicity and treatment results of
evaluable 20 patients are summarized in table 2.
Treatment plan evaluation
A dose superior to 70 Gy to PTV3 could be
attained with the 3-DCRT technique without
exceeding the predetermined limits of critical
structures tolerance (except for a mean dose for
both lungs). Seventeen patients received 74 Gy,
two patients had 72 Gy and one had 70 Gy. In
the latter case a total dose was not limited by the
predetermined tolerance criteria but by the
presence of concurrent heavy chronic respiratory
disease. Limits of 10% of dose inhomonogeity
within PTV3 were not reached in 45% of the
accepted treatment plans. This was caused by
too low photons energy (4MV) used (only
available in our institution for this purpose during
the study). The maximum dose to the spinal cord
was lower than 50 Gy, whereas one patient
received 52 Gy due to a technicians error. At
least 50% of the lung volume received <20 Gy in
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all patients. The level of the mean dose to the
lungs fixed below 20 Gy was exceeded in 5
cases. All these five- patients had stage III
disease, and three of them had a tumour located
in the inferior lobe. The mean volumes of PTV3
and PTV1 in this group were 251.6 cc and 617 cc
respectively, whereas in the group of patients
with the mean dose to both lungs below 20 Gy
the volumes for"'PTV3 and PTV1 were 169 cc and
453 cc respectively. The mean dose to both lungs
tended to increase with increasing irradiated
volumes. Dose constraints for heart and
oesophagus were observed in all patients.
Toxicity evaluation
Acute toxicity includes any toxicity occuring at
any time during the treatment, and the first 90
days after the end of the radiotherapy. Any
toxicity occuring after this period of time was
defined as late toxicity.
The Karnofsky Performance Status was
increased in 10% (2 patients), unchanged in
70% (14 patients), and decreased in 20% (4
patients). Deterioration in KPS was associated
with tumour progression in 3 patients, and in
one patient it was due to intercurrent liver
failure. Weight decreased in 20%, being
associated with tumour progression and non
treatment related. There was no acute
esophageal toxicity in 35% of patients, grade 1
occured in 40%, 20% experienced grade 2, and
only one patient (5%) developed grade 3, which
caused treatment interruption of 8 days. To date
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no late esophageal toxicity has been observed.
Acute pulmonary toxicity was assessed in 16
patients. Four patients were excluded from the
analysis. Two of them experienced rapid clinical
and radiological tumour progression and it was
impossible to distinguish the symptoms of the
disease from treatment toxicity. Two patients
died of an interrcurrent disease before the end
of the acute toxicity evaluation period (one
cardiac failure and one non tumour and
treatment related liver failure). Of the 16
evaluable patients four experienced radiation
pneumonitis. Three patients were scored as
grade 2 RTOG/EORTC acute pulmonary
toxicity, and all required corticosteroid therapy.
In one patient radiation pneumonitis had fatal
evolution (grade 5 RTOG/EORTC) despite
corticosteroid therapy from the third to the sixth
week after the end of radiotherapy. The CT of
the chest performed 4 days before the toxic
death showed partial regression of the tumour
and the image of radiation pneumonitis covered
the previous radiation area. To date the
evaluation of late pulmonary toxicity has been
performed only in 6 patients who met two
conditions: follow-up over 6 months without local
disease progression. There were no severe late
pulmonary complications that were attribuable to
the treatment for this group of patients. Only one
patient had grade 2 toxicity according to the
RTOG/EORTC, on all clinical and radiographic
findings (increase in steroids used for chronic
respiratory disease and moderate fibrosis). In
two patients, moderate fibrosis, as in grade 2
toxicity according to RTOG/EORTC scale, was
found without any clinical radiation-induced
pUlmonary symptoms. There were no signs of
pUlmonary toxicity in the remaining three cases.
Statistical evaluation of the relation of the mean
dose to both lungs and/or the pulmonary volume
receiving dose superior to 20 Gy and the
pulmonary toxicity was not feasible because of
the small number of events that occured.
Hovewer, one fatality occured in a patient with
the highest mean dose to both lungs, exceeding
the fixed dose constraint by 25%.
To date neither radiation-related cardiotoxicity
nor radiation myelopathy were observed.
Treatment responses and failure patterns
Of 20 patients, 17 (85%) were evaluable for
response. Treatment results are summarised in
Table 2.
Number Total dose Volume of Volume of Mean APT LPT Response
(in Gy) PTV1 PTV3 dose to to
both treatment
lungs
P1 74 815 400 25 5 PR
P2 74 569 192 22 2 2 PR
P3 74 438 196 21 2 NE PR
P4 70 302 117 11 0 2 NR
P5 74 322 111 17.5 0 0 CR
P6 74 658 283 15 NE NE PROGR
P7 74 637 262 21.5 0 NE PR
P8 74 627 208 21 0 2 PR
P9 74 226 75 19 0 0 CR
P10 72 750 141 13 0 0 NR
P11 74 520 61 19 0 NE PR
P12 72 555 304 19 NE NE NE
P13 74 439 189 15.5 0 NE NR
P14 74 380 135 18 NE NE NE
P15 74 366 191 16 NE NE PROGR
P16 74 438 206 17 2 NE NR
P17 74 560 231 15.5 0 NE PR
P18 74 555 208 14 0 NE CR
P19 74 311 104 14 0 NE CR
P20 72 417 178 17 0 NE NE
P21 treatment not completed (metastatic disease progression)
P22 error in treatment delivery
Abbreviations: APT=acute pulmonary toxicity according to EORTC/RTOG score, LPT=Jate pulmonary
toxicity according to EORTC/RTOG score, NE=non evaluated
CR=complete response, PR=partial response, NR=non-response, PROGR= progression
Table2. Number of patients (according to table 1), details on radiation therapy teChnique, treatment toxicity and results
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Two patients were excluded because of death
from an intercurrent disease before the
response assessement. In one patient the
follow-up period was too short. Of evaluable
patients, three (18%) - two in tumour stage I and
one in stage II - achieved complete radiological
response. In one patient, the complete response
was confirmed by bronchoscopy and biopsy.
Seven (41%) patients had a partial radiological
response, defined as superior to 50% tumour
regression. In 5 (29%) patients no change of
their tumour size has been noted. In two (12%)
patients, both in stage lilA with a weight loss
superior to 10% prior to treatment local tumor
progression occured. The response to treatment
was evaluated 6 weeks, 3 months and 6 months
after treatment completion. In two patients the
evaluation of the response to treatment was
hampered by the appearence of radiation-
related lung condensations in the treated
volume wrongly suggesting a tumour growth
which occured between the sixth week and the
third month. At evaluation within six months this
finding was verified and finally progression of
lung fibrosis with partial response to treatment
was diagnosed. To date no progression has
been observed within the treated volumes,
except for two above mentioned cases of
progression immediately following radiotherapy.
Distant metastases occured within the first 3
months of the follow-up in two patients with
partial thoracic response to radiotherapy. The
initial stage of both patients was lilA. One
patient with no radiological response to
treatment relapsed in the seventh month
outside the radiological field, in the homolateral
supraclavicular region and underwent salvage
radiotherapy with complete response.
Seventeen of 22 patients included in the study
(77%) are alive with a median follow-up of 220
days (range: 80-360). One died from acute
toxicity, two from an intercurrent disease and
two from distant relapse. Follow-up data are not
mature, and it is not possible at this point to
draw any firm conclusions concerning survival.
DISCUSSION
The rationale for the 3-DCRT is founded on
the results of many clinical and laboratory
studies concluding that enhancement of local
control results in a decreased metastatic spread
and increased survival in several types of
cancer (Leibel et aI., 1991; Suit, 1992). This
approach is particularly attractive in the
management of NSCLC because of poor local
control rate with conventional doses and
techniques of radiotherapy and high morbidity of
thoracic irradiation. Several studies on the use
of 3-DCRT with or without dose escalation with
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different degrees of technological advances in
the technique used in the management of
NSCLC have been published in the last decade
(Emami et aI., 1991; Armstrong et aI., 1997;
Robertson et aI., 1997; Derycke et aI., 1997).
Our study in this field has been based on 3-D
planning system using BEV for the selection of
beam directions and DVH for plan evaluation.
However, in the treatment delivery such tools
as asymmetric jaws, dynamic wedges, multileaf
collimators, portal imaging have not been yet
available. A 3-DCRT has been performed with
cerrobend blocks and conventional hard
wedges. Despite the absence of some tools
making treatment delivery more accurate, our
study enabled us to familiarise our staff with a
new approach in radiotherapy of the thoracic
tumours and acquire own experience in this
field.
The definition of a clinical target volume in 3-
DCRT remains controversial. Some authors
treated uninvolved mediastinal areas at least
with "prophylactic" doses (Armstrong et aI.,
1997), others included only involved areas
(Robertson et aI., 1997). Taking into account the
high probability of microscopic nodal invasion of
mediastinal nodes, S. Derycke et al. (Derycke et
aI., 1997) included in the CTV the nodal areas
with the probability of invasion exceeding 10%
according to the work of Minet et al. (Minet et
aI., 1993). The elective nodal irradiation largely
contributes to toxicity. The major dose-limiting
effect of radiotherapy for NSCLC is radiation
pneumonitis strongly dependent on the volume
of the irradiated lung (Martel et al;, 1994). In our
department in view of the limiting treatment
toxicity the above described scheme of limited
elective nodal irradiation has been elaborated
for this study. As in the work of Derycke et al.
(Derycke et aI., 1997), we based the rationale of
our radiotherapy scheme on the probability of
mediastinal nodal invasion in NSCLC derived
from thoracic surgery experience (Lewinski,
1965; Kiricuta et al. , 1994). The uninvolved
nodal areas with the probability of invasion
superior to 10% according to surgical data were
irradiated by 40-44 Gy and those with the
probability of invasion exceeding 20% received
56 Gy. Target volumes thus defined were
significantly reduced as compared with
"classical" elective fields, currently used in many
departments for the irradiation of NSCLC with
curative intent (Rocmans et aI., 1991). In our
study, one patient relapsed in homolateral
supraclavicular region outside the port. He
presented initially a metastatic involvement of
mediastinal nodes (group 4) and if a principle of
classical elective nodal irradiation had been
adopted, a region of relapse would have been
initially irradiated. The patient was successfully
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irradiated at relapse. The impact of relapse on
survival remained unclear. The necessity of
elective nodal irradiation needs further
investigations in phase III study and at least a
careful monitoring of pattern of loco-regional
failure is called for.
The lung tissue tolerance is one of the most
important dose-limiting factors in radiotherapy of
thoracic tumours. On the basis of clinical data,
Emami et al. (Emami et at., 1991) fixed a TD50
(end-point radiation pneumonitis) at 24.5 Gy (2
Gy per fraction) for the whole lung.
Consequently, it has become a common
procedure to limit the dose to the pulmonary
tissue to 20 Gy to at least 50% of the lung
volume. The estimation of the dose-volume
relation has now become more efficient as a
result of large availability of DVH. It has recently
been shown that the mean dose to both lungs
inferred from DVH appears to be a good
predictor of the lung toxicity (Theuws et aI.,
1998). In our study, we evaluated the DVH
derived parameters in order to predict the
toxicity. The follow-up period was found to be
too short, and a number of events not sufficient
for any further conclusions. However, the fact
that a fatality occured in a patient with the
highest mean dose for both lungs supports the
concept that a mean dose constraint fixed at 20
Gy should not be exceeded. If it is not possible
the treatment policy must be modified. We
decided that we shall include_ in the future
patients who need irradiation of such large
volumes (nodal stage'" in the lower lobe). The
analysis of pulmonary toxicity in our group of
patients is particularly difficult, because sixteen
(80%) of them presented chronic pulmonary
disease, and 95% were heavy smokers.
Damage to the pulmonary tissue prior to
radiotherapy seems to cause a decrease in the
tolerance level. This would require special
treatment planning techniques using functional
DVH based on pUlmonary perfusion from single
photon emission computed tomography
(SPECT). The pulmonary function tests (PFT),
prior to radiotherapy, seem to have a predictive
value in the determination of radiation-induced
whole lung dysfunction (Marks et aI., 1997). The
assessement of pulmonary toxicity using clinical
and/or radiological criteria, is of particularly
limited value in patients with concurrent
respiratory diseases, because of the difficulties
in differentiation of symptoms of radiation-
induced respiratory damage from a non-
treatment related worsening of a chronic
medical problem. Additionally, there is no clear
correlation between radiological and clinical
findings after radiotherapy (Arriagada et al.,
1989). PFT were not available for the majority of
analysed patients. At present, we continue our
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study with simultaneous evaluation of pre-RT
PFT and the same procedure repeated every 6
months during the follow-up period.
The planned 10% maximum dose
inhomonogeity within the PTV3 was not
achievable in 45% patients, mainly due to low
energy of the photons used (4MV). For high
energy of photons (over 10 MV) the treatment
planning systems tend to underestimate the
increase of the penumbra region due to changes
in photon and electron transport in the lung.
However, Emami et al. showed that there was
no difference between the dose distribution
when 4 vs.18 or 4 vS.10 MV photons beams
were used. The effect of increased percentage
depth dose for high energy beams tends to
disappear when multiple beams are used
(Emami et aI., 1991). In our stUdy the large
volumes receiving dose of 56 Gy limited the
number of beams used with the aim avoiding
overirradiation of large pulmonary volumes. The
use of conformal radiotherapy is an advantage
only in the case of small target volumes.
The high rate of complete responses in stage I
and II of NSCLC (50%) provide encouragement
for the continuation of the study in the early
tumour stages . This is in accordance with other
published data suggesting the maximum benefit
from conformal radiotherapy with dose
escalation in early-stage NSCLC. (Kupelian et
aI., 1996). No patient in stage III had radiological
complete response. However, partial responses
and "non-responses" need very careful
interpretation, because a short-term radiological
response in radiotherapy of NSCLC is not a 0
meaningfUl endpoint. There is no evident
correlation between radiotherapy response,
particularly that assessed by radiological means,
and survival. In the study of Mirimanoff et al.
(Mirimanoff et aI., 1998) 46% of 24 long-term
survivors (more than 3 years) were partial
responders and 29% of them did not respond
and there was even progressive disease in one
case. Early appearance of radiation-induced
fibrosis makes an estimation of response very
difficult. We have also encountered the same
problem of evaluation of radiological tumor
response during the follow-up. Five treatment
failures (two distant, one regional and two local
progression) occured in patients in stage III only.
Fifty-five percent evaluable stage '" patients
relapsed during a short follow-up period. These
results indicate that dose escalation using 3-
DCRT is not more effective than conventional
radiotherapy in the management of stage III of
NSCLC. There are promising results of the use
of combined radiation and chemotherapy or
accelerated fractionation schedules in stage III.
We suggest that 3-DCRT techniques should be
used in these new approaches to the
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management of stage III patients with favorable
prognostic factors in clearly designed and
carefully monitored clinical trials.
It may be concluded that the escalation of
dose up to 70 Gy is feasible with acceptable
acute toxicity. Maturation of follow-up data is
necessary to the proper evaluation of survival
and late toxicity. The necessity of applying
elective nodal irradiation needs fl!rther
investigations.
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